Stockscreener 앱 받기
3.25
1.88%
0.06
시장 영업 전:
3.25
Rocket Pharmaceuticals Inc 주식(RCKT)의 최신 뉴스
Rocket Pharmaceuticals Inc (RCKT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rocket Pharmaceuticals Inc (RCKT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
RCKT|Rocket Pharmaceuticals Inc|Price:3.240|Chg%:+0.050 - TradingKey
RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off - Stocktwits
If You Invested $1,000 in Rocket Pharmaceu (RCKT) - Stock Titan
Class Action Lawsuit Filed: Rocket Pharmaceuticals, Inc. (RCKT)Join by August 11, 2025Contact Levi & Korsinsky - The National Law Review
Rocket Pharmaceuticals, Inc. Revenue Breakdown – MUN:9IP1 - TradingView
Rocket Pharmaceuticals (RCKT) Stock Analysis: Exploring a Potential 186% Upside in Genetic Therapy Innovation - DirectorsTalk Interviews
Rocket Pharmaceuticals Inc (RCKT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rocket Pharmaceuticals Inc (RCKT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Frontier tech research, news & data - MLQ.ai
Rocket Pharmaceuticals stock steadies as gene therapy pipeline advances and cash runway extends - Ad-hoc-news.de
RCKT Stock Jumps Over 10% Premarket: FDA Approves Its First Gene Therapy For Rare Childhood Immune Disease - Stocktwits
ETFs Investing in Rocket Pharmaceuticals, Inc. Stocks - TradingView
Enterprise value to EBITDA forward of Rocket Pharmaceuticals, Inc. – DUS:9IP1 - TradingView
Enterprise value to revenue forward of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKTW - TradingView
RCKTW SEC FilingsROCKET PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Rocket Pharmaceuticals (RCKT) accounting chief reports 52,576-share RSU stake - Stock Titan
Price to earnings forward of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKTW - TradingView
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences - AOL.com
Form 144 ROCKET PHARMACEUTICALS For: 7 July By Investing.com - Investing.com South Africa
[144] ROCKET PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Number of shareholders of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKTW - TradingView
Director at Rocket Pharmaceuticals (RCKT) receives RSUs and stock options - Stock Titan
Rocket Pharmaceuticals (RCKT) director receives new RSU and stock option awards - Stock Titan
Price to book forward of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKTW - TradingView
Equity awards granted to RCKT director and 10% owner Roderick Wong - Stock Titan
Securities Lawsuit Alert: Rocket Pharmaceuticals, Inc. (RCKT)Contact Levi & Korsinsky Before August 11, 2025 - The National Law Review
Rocket Pharmaceuticals, Inc. Warrant 2023- on Rocket Pharmctc Financial Disclosures & SEC Filings - TradingView
RCKT Q1 2026 Earnings: Slight EPS Miss as Pre-Revenue Biotech Advances PipelineHigh Estimate Range - dars.gov.et
Rocket Pharmaceuticals Appoints Joseph Manhede as Principal Accounting Officer – SEC 8-K Filing June 2026 - Minichart
Rocket Pharmaceuticals (NASDAQ: RCKT) appoints new Principal Accounting Officer - Stock Titan
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) added to Russell Microcap Value Benchmark Index - marketscreener.com
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Rocket Pharmaceuticals, Inc.(NasdaqGM: RCKT) added to Russell Microcap Index - marketscreener.com
Rocket Pharmaceuticals, Inc.(NasdaqGM: RCKT) added to Russell 3000E Index - marketscreener.com
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Join Class Action to Recover Losses from Rocket Pharmaceuticals - The National Law Review
RCKT ALERT: Levi & Korsinsky Files Securities Fraud Class Action - The National Law Review
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi - The National Law Review
Investors Urged to Contact Levi & Korsinsky for Information Befor - The National Law Review
Rocket Pharmaceuticals, Inc. (RCKT) LawsuitInvestors Urged to Contact Levi & Korsinsky Before August 11, 2025 - The National Law Review
TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff - Stocktwits
Price to earnings forward of Rocket Pharmaceuticals, Inc. – BOATS:RCKTW - TradingView
Price to sales forward of Rocket Pharmaceuticals, Inc. – BOATS:RCKTW - TradingView
Enterprise value to revenue forward of Rocket Pharmaceuticals, Inc. – BOATS:RCKTW - TradingView
Rocket Pharma updates cash position after selling priority review voucher - MSN
1.97%
0.83%
자본화:
|
볼륨(24시간):